• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS.

作者信息

Soverini Simona, Martelli Margherita, Bavaro Luana, De Benedittis Caterina, Sica Simona, Sorà Federica, Iurlo Alessandra, Bonifacio Massimiliano, Pregno Patrizia, Galimberti Sara, Lunghi Francesca, Albano Francesco, D'Adda Mariella, Crugnola Monica, Capodanno Isabella, Castagnetti Fausto, Gugliotta Gabriele, Papayannidis Cristina, Rosti Gianantonio, Percesepe Antonio, Mignone Flavio, Baccarani Michele, Martinelli Giovanni, Cavo Michele

机构信息

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

Fondazione Policlinico Universitario A Gemelli-IRCCS, Istituto di Ematologia e Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Leukemia. 2021 Jul;35(7):2102-2107. doi: 10.1038/s41375-020-01098-w. Epub 2020 Dec 1.

DOI:10.1038/s41375-020-01098-w
PMID:33262525
Abstract
摘要

相似文献

1
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS.BCR-ABL1复合突变体：在一系列通过二代测序分析的费城染色体阳性白血病患者中，其发生率、谱系及与酪氨酸激酶抑制剂耐药性的相关性
Leukemia. 2021 Jul;35(7):2102-2107. doi: 10.1038/s41375-020-01098-w. Epub 2020 Dec 1.
2
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.二代测序提高费城染色体阳性急性淋巴细胞白血病中 BCR-ABL1 突变检测的灵敏度。
Br J Haematol. 2021 Apr;193(2):271-279. doi: 10.1111/bjh.17301. Epub 2021 Jan 6.
3
Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.下一代测序在伴有费城染色体阳性的成人急性淋巴细胞白血病患者中的 BCR-ABL1 激酶结构域突变检测中的应用：一篇立场文件。
Cancer Med. 2020 May;9(9):2960-2970. doi: 10.1002/cam4.2946. Epub 2020 Mar 10.
4
Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.使用大规模平行下一代测序技术检测赋予酪氨酸激酶抑制剂抗性的BCR-ABL1突变。
Ann Hematol. 2016 Jan;95(2):201-10. doi: 10.1007/s00277-015-2539-0. Epub 2015 Nov 10.
5
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.BCR-ABL1 复合突变合并关键激酶结构域位置可导致 Ph 染色体阳性白血病对 ponatinib 产生临床耐药性。
Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.
6
[3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia].
Rinsho Ketsueki. 2013 Oct;54(10):1682-6.
7
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.用于灵敏检测与伊马替尼耐药患者酪氨酸激酶抑制剂选择相关的BCR-ABL1突变的新一代测序技术。
Oncotarget. 2016 Apr 19;7(16):21982-90. doi: 10.18632/oncotarget.8010.
8
Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.二代测序揭示BCR-ABL1阳性白血病中普纳替尼耐药突变的动态演变
Br J Haematol. 2020 Dec;191(5):e113-e116. doi: 10.1111/bjh.17068. Epub 2020 Sep 10.
9
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.新一代深度测序可提高对慢性期慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗时出现的BCR-ABL1激酶结构域突变的检测率。
J Cancer Res Clin Oncol. 2015 May;141(5):887-99. doi: 10.1007/s00432-014-1845-6. Epub 2014 Nov 4.
10
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?慢性粒细胞白血病对酪氨酸激酶抑制剂的耐药性：实验室如何判定？
Lab Hematol. 2004;10(3):181-4.

引用本文的文献

1
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.2025年欧洲白血病网慢性髓性白血病管理建议
Leukemia. 2025 Jul 11. doi: 10.1038/s41375-025-02664-w.
2
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.对接受酪氨酸激酶抑制剂（TKI）治疗的白血病患者进行复杂BCR-ABL1激酶结构域突变的创新快速筛查。
Br J Cancer. 2025 Jun 30. doi: 10.1038/s41416-025-03098-y.
3
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.
阿西替尼在意大利多耐药慢性期慢性髓性白血病（CML-CP）患者群体中同情用药的真实世界疗效概况。
Hematol Oncol. 2025 May;43(3):e70101. doi: 10.1002/hon.70101.
4
Molecular techniques in haematopathology: what and how?血液病理学中的分子技术：是什么以及如何应用？
Histopathology. 2025 Jan;86(1):38-57. doi: 10.1111/his.15332. Epub 2024 Oct 15.
5
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.在伴有复合突变的慢性髓性白血病急变期临床前模型中，泊那替尼与阿伐替尼的联合疗法。
Leukemia. 2024 Jun;38(6):1415-1418. doi: 10.1038/s41375-024-02248-0. Epub 2024 Apr 13.
6
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.一种整合分子反应、毒性和血浆水平指标的新算法，用于慢性髓性白血病患者泊那替尼剂量选择
Pharmaceutics. 2024 Mar 11;16(3):383. doi: 10.3390/pharmaceutics16030383.
7
Resistance mutations in CML and how we approach them.CML 中的耐药突变及其应对策略。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):469-475. doi: 10.1182/hematology.2023000447.
8
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。
Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.
9
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.利用液滴数字 PCR 技术检测慢性髓性白血病中第二代酪氨酸激酶抑制剂耐药的 BCR::ABL1 激酶结构域突变。
Leukemia. 2022 Sep;36(9):2250-2260. doi: 10.1038/s41375-022-01660-8. Epub 2022 Jul 30.
10
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.克服对激酶抑制剂的耐药性：慢性髓性白血病的范例
Onco Targets Ther. 2022 Jan 25;15:103-116. doi: 10.2147/OTT.S289306. eCollection 2022.